11/21
04:10 am
rxrx
Familial Adenomatous Polyposis Pipeline Landscape Report 2024 [Yahoo! Finance]
Medium
Report
Familial Adenomatous Polyposis Pipeline Landscape Report 2024 [Yahoo! Finance]
11/20
12:50 pm
rxrx
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
11/20
07:00 am
rxrx
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Medium
Report
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
11/13
09:08 am
rxrx
Recursion and Exscientia Shareholders Approve the Proposed Combination
Medium
Report
Recursion and Exscientia Shareholders Approve the Proposed Combination
11/12
04:54 pm
rxrx
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
Medium
Report
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
11/10
09:02 am
rxrx
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher [Yahoo! Finance]
Medium
Report
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher [Yahoo! Finance]
11/7
08:36 am
rxrx
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Low
Report
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
11/6
08:28 pm
rxrx
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/6
04:15 pm
rxrx
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
Medium
Report
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
11/5
07:56 am
rxrx
Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
11/1
07:00 pm
rxrx
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
10/30
08:22 am
rxrx
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Low
Report
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
10/24
07:32 pm
rxrx
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know [Yahoo! Finance]
10/22
08:00 am
rxrx
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Low
Report
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
10/17
09:51 am
rxrx
Prediction: These 2 Stocks Could Soar in 2025 [Yahoo! Finance]
Medium
Report
Prediction: These 2 Stocks Could Soar in 2025 [Yahoo! Finance]
10/17
05:24 am
rxrx
Iktos appoints new Scientific Advisory Board with world-renowned AI and Drug Discovery experts to accelerate the development of novel therapies [Yahoo! Finance]
Medium
Report
Iktos appoints new Scientific Advisory Board with world-renowned AI and Drug Discovery experts to accelerate the development of novel therapies [Yahoo! Finance]
10/15
07:49 pm
rxrx
Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know [Yahoo! Finance]
Medium
Report
Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know [Yahoo! Finance]
10/11
04:30 pm
rxrx
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI
10/10
08:30 am
rxrx
Machine Learning In Our Daily Lives [Forbes]
Low
Report
Machine Learning In Our Daily Lives [Forbes]
10/2
07:50 pm
rxrx
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]
10/2
08:00 am
rxrx
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Low
Report
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
9/23
07:13 pm
rxrx
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]
9/12
11:09 am
rxrx
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock [Yahoo! Finance]
9/4
05:15 pm
rxrx
Recursion: Path Forward For REC-994 Remains Despite Mixed Response [Seeking Alpha]
Low
Report
Recursion: Path Forward For REC-994 Remains Despite Mixed Response [Seeking Alpha]
9/4
12:32 pm
rxrx
Recursion Stock Down Despite Meeting Goal in Brain Disease Study [Yahoo! Finance]
Low
Report
Recursion Stock Down Despite Meeting Goal in Brain Disease Study [Yahoo! Finance]